Anti-Human LAMP5 Recombinant Antibody (CAT#: TAB-483CL)

Gracia-Maldonado, Gabriel, et al. "LAMP-5 is an essential inflammatory-signaling regulator and novel immunotherapy target for mixed lineage leukemia-rearranged acute leukemia." Haematologica 107.4 (2021): 803. https://doi.org/10.3324/haematol.2020.257451

This research investigates LAMP-5 (lysosomal associated membrane protein 5) as a critical target in mixed lineage leukemia-rearranged (MLL-r) acute leukemias. The study demonstrates that LAMP5 is highly and specifically expressed in MLL-r leukemias compared to MLL-germline leukemias, and is directly regulated by the MLL-fusion protein. Through functional studies, the researchers reveal that LAMP-5 plays an essential role in leukemia cell survival both in vitro and in vivo by modulating innate immune signaling pathways. Specifically, LAMP-5 facilitates the transfer of signals from interferon signaling endosomes to pro-inflammatory signaling endosomes, inhibiting NF-κB activation while enhancing type-1 interferon signaling. Importantly, the researchers detected LAMP-5 on the surface of MLL-r leukemia cells, enabling targeted therapy approaches.
Creative Biolabs provided the therapeutic antibody targeting human LAMP-5 that was used in the antibody-drug conjugate experiments. The antibody enabled the researchers to specifically detect LAMP-5 on the cell surface of MLL-r leukemia cells and, when combined with anti-mouse IgG Fc-DM1 antibody with non-cleavable linker, demonstrated significant anti-leukemic activity against MLL-r leukemia cell lines while sparing MLL-germline cells. This provided crucial proof-of-concept evidence that LAMP-5 could serve as a novel immunotherapeutic target with a potentially wide therapeutic window for treating MLL-r leukemias, which currently have limited treatment options and poor clinical outcomes.